Skip to main content

Main menu

  • Home
  • Content
    • Early Access
    • Current Issue
    • Kidney360 Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Clinical Images
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
    • Editorial Team
    • Editorial Training Program
    • Reviewer Recognition
  • More
    • About Kidney360
    • Advertising
    • Email Alerts
    • Feedback
    • Reprint Information
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • CJASN
    • Kidney News Online
    • American Society of Nephrology

User menu

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • CJASN
    • Kidney News Online
    • American Society of Nephrology
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Early Access
    • Current Issue
    • Kidney360 Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Clinical Images
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Editorial Team
    • Editorial Team
    • Editorial Training Program
    • Reviewer Recognition
  • More
    • About Kidney360
    • Advertising
    • Email Alerts
    • Feedback
    • Reprint Information
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow Kidney360 on Twitter
  • Community Forum
  • Kidney360 RSS
Editorial

Impact of Metabolic Acidosis and Alkali Therapy on Linear Growth in Children with Chronic Kidney Disease: What Is the Current Evidence?

Emma H. Ulrich and Rahul Chanchlani
Kidney360 April 2022, 3 (4) 590-596; DOI: https://doi.org/10.34067/KID.0000072022
Emma H. Ulrich
1Division of Pediatric Nephrology, Department of Pediatrics, University of Alberta, Edmonton, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Emma H. Ulrich
Rahul Chanchlani
2ICES, Toronto, Canada
3Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada
4Division of Pediatric Nephrology, Department of Pediatrics, McMaster University, Hamilton, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rahul Chanchlani
  • Article
  • Figures & Data Supps
  • Info & Metrics
  • View PDF
Loading
  • chronic kidney disease
  • acidosis
  • alkali
  • children
  • end stage kidney disease
  • growth
  • height

CKD in childhood is associated with multiple comorbidities, including growth failure (1⇓⇓–4). Earlier detection and management of reduced growth velocity have enhanced the growth potential for children with CKD (5). Despite these advances, nearly half of prepubertal children with ESKD will have short stature in adulthood (height <3rd percentile) (1,6,7). Short stature at initiation of dialysis is associated with increased risk of death and dialysis-related complications (8), and short stature pretransplant is associated with reduced graft survival (9). Impaired growth also places significant psychosocial burdens on the child and family, including reduced quality of life and ability for social advancement (10⇓–12). The etiology of growth impairment in CKD is multifactorial, including growth hormone (GH) resistance, salt wasting, metabolic acidosis, proteinuria, malnutrition, and anemia (3,13).

Metabolic acidosis is widely recognized as a cause of poor growth, and consensus guidelines recommend maintaining serum bicarbonate ≥22 mEq/L in children with CKD (2,14). There are several hypothesized mechanisms. Animal models suggest that acidosis activates catabolic pathways, leading to impaired muscle development (15) and protein wasting (16), and increased inflammation and cytokine release (17,18). Acidosis disrupts the somatotropic hormone axis, including reduced expression of IGF-1 and GH receptors, reduced IGF-1 levels and resistance to GH secretion, and reduced cellular proliferation at skeletal growth plates (19⇓⇓–22). However, few pediatric studies have examined whether metabolic acidosis is independently associated with growth failure in children with CKD (23⇓–25).

In this issue of Kidney360, Brown et al. (26) seek to characterize better the effect of metabolic acidosis, and treatment with alkali therapy, on linear growth in a large cohort of children with CKD in a longitudinal observational cohort study. The authors analyzed data from the Chronic Kidney Disease in Children (CKiD) study—a prospective, multicenter cohort of children with mild-moderate kidney impairment (eGFR 30–90 ml/min per 1.73 m2) (27). The authors included 1082 children 2–20 years of age, stratified by CKD diagnosis: nonglomerular (n=808) and glomerular disease (n=274). Serum bicarbonate was used as a surrogate marker of metabolic acidosis, defined as normal (≥22 mEq/L), low (19–22 mEq/L), and very low (≤18 mEq/L); height z score was the primary outcome. Adjusted analyses were reported using repeated-measures linear regression models, controlling for relevant demographic variables (age, sex, abnormal birth history, mid-parental height), eGFR (measured, if available), proteinuria, abnormal calcium or phosphate, intact parathyroid hormone, and CKD duration (years).

The authors reported four principal findings: (1) low and very low serum bicarbonate levels are associated with reduced height at baseline; (2) low and very low serum bicarbonate levels are associated with worse height z scores in children with CKD due to nonglomerular disease but not in glomerular disease; (3) metabolic acidosis has a greater adverse effect on height among children with nonglomerular disease and eGFR <45 ml/min per 1.73 m2; and (4) among children ≤13 years of age (i.e., prepubertal), treatment with alkali therapy is positively associated with improved growth.

Strengths

We have summarized the results of prior studies examining the effect of metabolic acidosis and/or its treatment on growth in children since 1975 (23⇓–25,28⇓⇓⇓⇓⇓⇓⇓⇓–37) (Table 1). Current evidence regarding metabolic acidosis and its association with growth impairment is mainly limited to populations with renal tubular acidosis (23,28⇓⇓⇓⇓⇓–34,37) and has not been longitudinally studied in children with CKD. The study by Brown et al. (26) aims to fill this knowledge gap and reports novel findings that treatment of metabolic acidosis with alkali therapy improves growth in children with CKD.

View this table:
  • View inline
  • View popup
Table 1.

Summary of pediatric studies of association between metabolic acidosis and linear growth in children with or without CKD

The other strength is the uniqueness of the CKiD study, in which data are collected across 50 centers in North America, representing a heterogeneous, ethnically diverse population of children (27). These data increase the generalizability of the results obtained, which has been an important limitation of previous single-center studies (28⇓⇓⇓⇓⇓⇓–35,37).

Finally, the study findings draw particular attention to the undertreatment of metabolic acidosis in children with CKD in this cohort. Despite consensus recommendations to maintain normal serum bicarbonate levels, alkali therapy was reported in only 34% (122/360) of children with nonglomerular disease and 16% (16/97) of children with glomerular disease with low or very low serum bicarbonate levels (<22 mEq/L). Poor medication adherence has previously been reported in children with CKD and is recognized as an important modifiable factor in improving growth (38). This finding suggests that under-recognition and/or undertreatment of metabolic acidosis contributes to short stature in adults with a history of CKD in childhood.

Limitations

The main limitations reflect the challenge of studying growth in children with CKD using an observational study design. Growth impairment in children with CKD is multifactorial and highly complex. The authors performed adjusted analyses to account for relevant comorbidities but were limited by the availability of data for some variables, including measured GFR and nutrition status.

Another important limitation of the study is that time-varying effects of confounders, especially GFR, could not be accounted for in the analysis. Previous studies in children with CKD have shown that worsening GFR is associated with worsening acidosis (36,39); furthermore, acidosis has also been associated with CKD progression (36,40⇓–42). In addition, measured GFR was missing in approximately half of the cohort. Although measuring GFR is often impractical and resource intensive (3,43⇓–45) in children, eGFR is less accurate at higher severity of CKD due to increased tubular secretion of creatinine, and measured GFR remains the gold standard (46). To address some of these limitations, the authors performed additional analyses in which GFR was analyzed as an effect modifier. In this analysis, both eGFR and measured GFR were stratified into two categories—≥45 and <45 ml/min per 1.73 m2—to examine further the association between metabolic acidosis and height within GFR groups. Results showed that in children with nonglomerular disease, low and very low serum bicarbonate levels were associated with impaired growth at GFR <45 ml/min per 1.73 m2 only. However, using measured GFR, very low serum bicarbonate levels was associated with impaired growth in both GFR categories. The study findings were unchanged and remained nonsignificant in children with glomerular CKD. Although CKD duration was included as a covariate, children with glomerular diseases were older, had a shorter duration of CKD, and were generally taller, which could explain the discrepant results. These supplemental analyses suggest that the true effect of CKD in the analyses requires further study.

The authors also noted that only 10% of the children in the overall cohort were using GH during the study period. However, sensitivity analysis excluding children treated with GH did not yield different results in children with nonglomerular disease. Other important covariates were not reflected in the study. Although mid-parental height was included in adjusted analyses, the authors do not account for prenatal factors and syndromic short stature (1,35). There was also limited nutritional data in the study. Although only 4% of the cohort was underweight by body mass index, nutritional management undoubtedly serves an important role in the management of children with CKD and impaired growth (47⇓⇓–50). Anemia is also an important contributor to impaired growth (51,52), and anemia severity may be affected by metabolic acidosis (53). Although the authors note that there were significantly higher rates of anemia in the very low bicarbonate group, this was not accounted for in the adjusted models. Finally, although calcium, phosphate, and intact parathyroid hormone were included in the adjusted models, the authors were not able to report on vitamin D data and other hormonal disturbances (i.e., hypothyroidism), which all play a role in adequate growth in children with CKD (54).

Conclusions

Despite these limitations, this study by Brown et al. (26) presents clinically relevant evidence of the deleterious effect of metabolic acidosis on growth in children with CKD. The study also underscores the importance of alkali therapy on improved growth in this cohort. This relatively inexpensive, well-tolerated, and conservative approach to optimizing linear growth can have a profound effect on long-term morbidity and social integration in this population (14,55,56).

Larger observational studies, accounting for time-varying comorbidities, will further strengthen our understanding of the effect of metabolic acidosis in CKD. Future randomized controlled trials studying the potential dose-dependent effects of alkali therapy on linear growth are also needed.

Future studies should also assess the effect and treatment of metabolic acidosis on other CKD comorbidities. Previous evidence suggests that acidosis may contribute to CKD progression and other nutritional parameters (23,36,40,55,57); small studies have also shown that alkali therapy may improve nutritional status and quality of life (41). Furthermore, studies are needed to examine the effect of acidosis on neurodevelopmental and patient-reported outcomes, including quality of life and mental health.

Children with CKD and their families face tremendous physical and psychosocial burdens. Growth impairment is well-established in children with CKD and results in significant morbidity. Treatment of metabolic acidosis may be a particularly effective option for improving outcomes in this population.

Disclosures

All authors have nothing to disclose.

Funding

None.

Acknowledgments

The content of this article reflects the personal experience and views of the author(s) and should not be considered medical advice or recommendations. The content does not reflect the views or opinions of the American Society of Nephrology (ASN) or Kidney360. Responsibility for the information and views expressed herein lies entirely with the author(s).

Author Contributions

R. Chanchlani was responsible for methodology and supervision; and both authors wrote the original draft of the manuscript and reviewed and edited the manuscript.

Footnotes

  • See related article, “Longitudinal Associations between Low Serum Bicarbonate and Linear Growth in Children with Chronic Kidney Disease” on pages 666–676.

  • Received February 4, 2022.
  • Accepted March 9, 2022.
  • Copyright © 2022 by the American Society of Nephrology

References

  1. ↵
    1. Drube J,
    2. Wan M,
    3. Bonthuis M,
    4. Wühl E,
    5. Bacchetta J,
    6. Santos F,
    7. Grenda R,
    8. Edefonti A,
    9. Harambat J,
    10. Shroff R,
    11. Tönshoff B,
    12. Haffner D; European Society for Paediatric Nephrology Chronic Kidney Disease Mineral and Bone Disorders, Dialysis, and Transplantation Working Groups
    : Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. Nat Rev Nephrol 15: 577–589, 2019 https://doi.org/10.1038/s41581-019-0161-4
    OpenUrl
  2. ↵
    1. National Kidney Foundation. KDOQI
    : Clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Available at https://kidneyfoundation.cachefly.net/professionals/KDOQI/guidelines_pedbone/guide14.htm. Accessed February 3, 2022
  3. ↵
    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group
    : KDIGO 2012 Clinical practice guideline for the evaluation and management of chronic kidney disease. Available at https://kdigo.org/guidelines/ckd-evaluation-and-management/. Accessed: February 3, 2022
  4. ↵
    1. Geary DF,
    2. Schaefer F
    , editors: Pediatric Kidney Disease, 2nd Ed., Berlin, Springer, 2016 https://doi.org/10.1007/978-3-662-52972-0
  5. ↵
    1. André JL,
    2. Bourquard R,
    3. Guillemin F,
    4. Krier MJ,
    5. Briançon S
    : Final height in children with chronic renal failure who have not received growth hormone. Pediatr Nephrol 18: 685–691, 2003 https://doi.org/10.1007/s00467-003-1145-x
    OpenUrlPubMed
  6. ↵
    1. Harambat J,
    2. Bonthuis M,
    3. van Stralen KJ,
    4. Ariceta G,
    5. Battelino N,
    6. Bjerre A,
    7. Jahnukainen T,
    8. Leroy V,
    9. Reusz G,
    10. Sandes AR,
    11. Sinha MD,
    12. Groothoff JW,
    13. Combe C,
    14. Jager KJ,
    15. Verrina E,
    16. Schaefer F; ESPN/ERA-EDTA Registry
    : Adult height in patients with advanced CKD requiring renal replacement therapy during childhood. Clin J Am Soc Nephrol 9: 92–99, 2014 https://doi.org/10.2215/CJN.00890113
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Fine RN,
    2. Martz K,
    3. Stablein D
    : What have 20 years of data from the North American Pediatric Renal Transplant Cooperative Study taught us about growth following renal transplantation in infants, children, and adolescents with end-stage renal disease? Pediatr Nephrol 25: 739–746, 2010 https://doi.org/10.1007/s00467-009-1387-3
    OpenUrlCrossRefPubMed
  8. ↵
    1. Furth SL,
    2. Stablein D,
    3. Fine RN,
    4. Powe NR,
    5. Fivush BA
    : Adverse clinical outcomes associated with short stature at dialysis initiation: A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatrics 109: 909–913, 2002 https://doi.org/10.1542/peds.109.5.909
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Li Y,
    2. Greenbaum LA,
    3. Warady BA,
    4. Furth SL,
    5. Ng DK
    : Short stature in advanced pediatric CKD is associated with faster time to reduced kidney function after transplant. Pediatr Nephrol 34: 897–905, 2019 https://doi.org/10.1007/s00467-018-4165-2
    OpenUrl
  10. ↵
    1. Al-Uzri A,
    2. Matheson M,
    3. Gipson DS,
    4. Mendley SR,
    5. Hooper SR,
    6. Yadin O,
    7. Rozansky DJ,
    8. Moxey-Mims M,
    9. Furth SL,
    10. Warady BA,
    11. Gerson AC; Chronic Kidney Disease in Children Study Group
    : The impact of short stature on health-related quality of life in children with chronic kidney disease. J Pediatr 163: 736–41.e1, 2013 https://doi.org/10.1016/j.jpeds.2013.03.016
    OpenUrlCrossRefPubMed
  11. ↵
    1. Rosenkranz J,
    2. Reichwald-Klugger E,
    3. Oh J,
    4. Turzer M,
    5. Mehls O,
    6. Schaefer F
    : Psychosocial rehabilitation and satisfaction with life in adults with childhood-onset of end-stage renal disease. Pediatr Nephrol 20: 1288–1294, 2005 https://doi.org/10.1007/s00467-005-1952-3
    OpenUrlCrossRefPubMed
  12. ↵
    1. Broyer M,
    2. Le Bihan C,
    3. Charbit M,
    4. Guest G,
    5. Tete MJ,
    6. Gagnadoux MF,
    7. Niaudet P
    : Long-term social outcome of children after kidney transplantation. Transplantation 77: 1033–1037, 2004 https://doi.org/10.1097/01.TP.0000120947.75697.8B
    OpenUrlCrossRefPubMed
  13. ↵
    1. Haffner D
    : Strategies for optimizing growth in children with chronic kidney disease. Front Pediatr 8: 399, 2020 https://doi.org/10.3389/fped.2020.00399
    OpenUrl
  14. ↵
    1. Kraut JA,
    2. Madias NE
    : Consequences and therapy of the metabolic acidosis of chronic kidney disease. Pediatr Nephrol 26: 19–28, 2011 https://doi.org/10.1007/s00467-010-1564-4
    OpenUrlCrossRefPubMed
  15. ↵
    1. Bailey JL,
    2. Wang X,
    3. England BK,
    4. Price SR,
    5. Ding X,
    6. Mitch WE
    : The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest 97: 1447–1453, 1996 https://doi.org/10.1172/JCI118566
    OpenUrlCrossRefPubMed
  16. ↵
    1. Boirie Y,
    2. Broyer M,
    3. Gagnadoux MF,
    4. Niaudet P,
    5. Bresson JL
    : Alterations of protein metabolism by metabolic acidosis in children with chronic renal failure. Kidney Int 58: 236–241, 2000 https://doi.org/10.1046/j.1523-1755.2000.00158.x
    OpenUrlCrossRefPubMed
  17. ↵
    1. Eustace JA,
    2. Astor B,
    3. Muntner PM,
    4. Ikizler TA,
    5. Coresh J
    : Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease. Kidney Int 65: 1031–1040, 2004 https://doi.org/10.1111/j.1523-1755.2004.00481.x
    OpenUrlCrossRefPubMed
  18. ↵
    1. Bellocq A,
    2. Suberville S,
    3. Philippe C,
    4. Bertrand F,
    5. Perez J,
    6. Fouqueray B,
    7. Cherqui G,
    8. Baud L
    : Low environmental pH is responsible for the induction of nitric-oxide synthase in macrophages. Evidence for involvement of nuclear factor-kappaB activation. J Biol Chem 273: 5086–5092, 1998 https://doi.org/10.1074/jbc.273.9.5086
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Karava V,
    2. Dotis J,
    3. Christoforidis A,
    4. Kondou A,
    5. Printza N
    : Muscle-bone axis in children with chronic kidney disease: Current knowledge and future perspectives. Pediatr Nephrol 36: 3813–3827, 2020 https://doi.org/10.1007/s00467-021-04936-w
    OpenUrl
  20. ↵
    1. Green J,
    2. Maor G
    : Effect of metabolic acidosis on the growth hormone/IGF-I endocrine axis in skeletal growth centers. Kidney Int 57: 2258–2267, 2000 https://doi.org/10.1046/j.1523-1755.2000.00086.x
    OpenUrlCrossRefPubMed
  21. ↵
    1. Goldberg R,
    2. Reshef-Bankai E,
    3. Coleman R,
    4. Green J,
    5. Maor G
    : Chronic acidosis-induced growth retardation is mediated by proton-induced expression of Gs protein. J Bone Miner Res 21: 703–713, 2006 https://doi.org/10.1359/jbmr.060210
    OpenUrlCrossRefPubMed
  22. ↵
    1. Brüngger M,
    2. Hulter HN,
    3. Krapf R
    : Effect of chronic metabolic acidosis on the growth hormone/IGF-1 endocrine axis: New cause of growth hormone insensitivity in humans. Kidney Int 51: 216–221, 1997 https://doi.org/10.1038/ki.1997.26
    OpenUrlCrossRefPubMed
  23. ↵
    1. Lopez-Garcia SC,
    2. Emma F,
    3. Walsh SB,
    4. Fila M,
    5. Hooman N,
    6. Zaniew M,
    7. Bertholet-Thomas A,
    8. Colussi G,
    9. Burgmaier K,
    10. Levtchenko E,
    11. Sharma J,
    12. Singhal J,
    13. Soliman NA,
    14. Ariceta G,
    15. Basu B,
    16. Murer L,
    17. Tasic V,
    18. Tsygin A,
    19. Decramer S,
    20. Gil-Peña H,
    21. Koster-Kamphuis L,
    22. La Scola C,
    23. Gellermann J,
    24. Konrad M,
    25. Lilien M,
    26. Francisco T,
    27. Tramma D,
    28. Trnka P,
    29. Yüksel S,
    30. Caruso MR,
    31. Chromek M,
    32. Ekinci Z,
    33. Gambaro G,
    34. Kari JA,
    35. König J,
    36. Taroni F,
    37. Thumfart J,
    38. Trepiccione F,
    39. Winding L,
    40. Wühl E,
    41. Ağbaş A,
    42. Belkevich A,
    43. Vargas-Poussou R,
    44. Blanchard A,
    45. Conti G,
    46. Boyer O,
    47. Dursun I,
    48. Pınarbaşı AS,
    49. Melek E,
    50. Miglinas M,
    51. Novo R,
    52. Mallett A,
    53. Milosevic D,
    54. Szczepanska M,
    55. Wente S,
    56. Cheong HI,
    57. Sinha R,
    58. Gucev Z,
    59. Dufek S,
    60. Iancu D,
    61. Kleta R,
    62. Schaefer F,
    63. Bockenhauer D; European dRTA Consortium
    : Treatment and long-term outcome in primary distal renal tubular acidosis. Nephrol Dial Transplant 34: 981–991, 2019 https://doi.org/10.1093/ndt/gfy409
    OpenUrl
  24. ↵
    1. Rodig NM,
    2. McDermott KC,
    3. Schneider MF,
    4. Hotchkiss HM,
    5. Yadin O,
    6. Seikaly MG,
    7. Furth SL,
    8. Warady BA
    : Growth in children with chronic kidney disease: A report from the Chronic Kidney Disease in Children Study. Pediatr Nephrol 29: 1987–1995, 2014 https://doi.org/10.1007/s00467-014-2812-9
    OpenUrlCrossRefPubMed
  25. ↵
    1. Seikaly MG,
    2. Salhab N,
    3. Gipson D,
    4. Yiu V,
    5. Stablein D
    : Stature in children with chronic kidney disease: Analysis of NAPRTCS database. Pediatr Nephrol 21: 793–799, 2006 https://doi.org/10.1007/s00467-006-0040-7
    OpenUrlCrossRefPubMed
  26. ↵
    1. Brown D,
    2. Carroll M,
    3. Ng D,
    4. Levy R,
    5. Greenbaum L,
    6. Kaskel F,
    7. Furth S,
    8. Warady B,
    9. Melamed M,
    10. Dauber A
    : Longitudinal associations between low serum bicarbonate and linear growth in children with chronic kidney disease. Kidney360 3: 666–676, 2022 https://doi.org/10.34067/KID.0005402021
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Furth SL,
    2. Cole SR,
    3. Moxey-Mims M,
    4. Kaskel F,
    5. Mak R,
    6. Schwartz G,
    7. Wong C,
    8. Muñoz A,
    9. Warady BA
    : Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol 1: 1006–1015, 2006 https://doi.org/10.2215/CJN.01941205
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. McSherry E,
    2. Morris RC Jr.
    : Attainment and maintenance of normal stature with alkali therapy in infants and children with classic renal tubular acidosis. J Clin Invest 61: 509–527, 1978 https://doi.org/10.1172/JCI108962
    OpenUrlCrossRefPubMed
  29. ↵
    1. Caldas A,
    2. Broyer M,
    3. Dechaux M,
    4. Kleinknecht C
    : Primary distal tubular acidosis in childhood: Clinical study and long-term follow-up of 28 patients. J Pediatr 121: 233–241, 1992 https://doi.org/10.1016/S0022-3476(05)81194-1
    OpenUrlCrossRefPubMed
  30. ↵
    1. Chang CY,
    2. Lin CY
    : Failure to thrive in children with primary distal type renal tubular acidosis. Acta Paediatr Taiwan 43: 334–339, 2002
    OpenUrlPubMed
  31. ↵
    1. Bajpai A,
    2. Bagga A,
    3. Hari P,
    4. Bardia A,
    5. Mantan M
    : Long-term outcome in children with primary distal renal tubular acidosis. Indian Pediatr 42: 321–328, 2005
    OpenUrlPubMed
  32. ↵
    1. Hsu SY,
    2. Tsai IJ,
    3. Tsau YK
    : Comparison of growth in primary Fanconi syndrome and proximal renal tubular acidosis. Pediatr Nephrol 20: 460–464, 2005 https://doi.org/10.1007/s00467-004-1771-y
    OpenUrlPubMed
  33. ↵
    1. Sharma AP,
    2. Singh RN,
    3. Yang C,
    4. Sharma RK,
    5. Kapoor R,
    6. Filler G
    : Bicarbonate therapy improves growth in children with incomplete distal renal tubular acidosis. Pediatr Nephrol 24: 1509–1516, 2009 https://doi.org/10.1007/s00467-009-1169-y
    OpenUrlPubMed
  34. ↵
    1. Besouw MTP,
    2. Bienias M,
    3. Walsh P,
    4. Kleta R,
    5. Van’t Hoff WG,
    6. Ashton E,
    7. Jenkins L,
    8. Bockenhauer D
    : Clinical and molecular aspects of distal renal tubular acidosis in children [published correction appears in Pediatr Nephrol 32: 1095, 2017 10.1007/s00467-017-3631-6]. Pediatr Nephrol 32: 987–996, 2017 https://doi.org/10.1007/s00467-016-3573-4
    OpenUrlCrossRefPubMed
  35. ↵
    1. Franke D,
    2. Steffens R,
    3. Thomas L,
    4. Pavičić L,
    5. Ahlenstiel T,
    6. Pape L,
    7. Gellermann J,
    8. Müller D,
    9. Querfeld U,
    10. Haffner D,
    11. Živičnjak M
    : Kidney transplantation fails to provide adequate growth in children with chronic kidney disease born small for gestational age. Pediatr Nephrol 32: 511–519, 2017 https://doi.org/10.1007/s00467-016-3503-5
    OpenUrl
  36. ↵
    1. Harambat J,
    2. Kunzmann K,
    3. Azukaitis K,
    4. Bayazit AK,
    5. Canpolat N,
    6. Doyon A,
    7. Duzova A,
    8. Niemirska A,
    9. Sözeri B,
    10. Thurn-Valsassina D,
    11. Anarat A,
    12. Bessenay L,
    13. Candan C,
    14. Peco-Antic A,
    15. Yilmaz A,
    16. Tschumi S,
    17. Testa S,
    18. Jankauskiene A,
    19. Erdogan H,
    20. Rosales A,
    21. Alpay H,
    22. Lugani F,
    23. Arbeiter K,
    24. Mencarelli F,
    25. Kiyak A,
    26. Dönmez O,
    27. Drozdz D,
    28. Melk A,
    29. Querfeld U,
    30. Schaefer F; 4C Study Consortium
    : Metabolic acidosis is common and associates with disease progression in children with chronic kidney disease. Kidney Int 92: 1507–1514, 2017 https://doi.org/10.1016/j.kint.2017.05.006
    OpenUrlPubMed
  37. ↵
    1. Atmis B,
    2. Cevizli D,
    3. Melek E,
    4. Bisgin A,
    5. Unal I,
    6. Anarat A,
    7. Bayazit AK
    : Evaluation of phenotypic and genotypic features of children with distal kidney tubular acidosis. Pediatr Nephrol 35: 2297–2306, 2020 https://doi.org/10.1007/s00467-020-04685-2
    OpenUrl
  38. ↵
    1. Akchurin OM,
    2. Schneider MF,
    3. Mulqueen L,
    4. Brooks ER,
    5. Langman CB,
    6. Greenbaum LA,
    7. Furth SL,
    8. Moxey-Mims M,
    9. Warady BA,
    10. Kaskel FJ,
    11. Skversky AL
    : Medication adherence and growth in children with CKD. Clin J Am Soc Nephrol 9: 1519–1525, 2014 https://doi.org/10.2215/CJN.01150114
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Wong H,
    2. Mylrea K,
    3. Feber J,
    4. Drukker A,
    5. Filler G
    : Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney Int 70: 585–590, 2006 https://doi.org/10.1038/sj.ki.5001608
    OpenUrlCrossRefPubMed
  40. ↵
    1. Brown DD,
    2. Roem J,
    3. Ng DK,
    4. Reidy KJ,
    5. Kumar J,
    6. Abramowitz MK,
    7. Mak RH,
    8. Furth SL,
    9. Schwartz GJ,
    10. Warady BA,
    11. Kaskel FJ,
    12. Melamed ML
    : Low serum bicarbonate and CKD progression in children. Clin J Am Soc Nephrol 15: 755–765, 2020 https://doi.org/10.2215/CJN.07060619
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. de-Brito Ashurst I,
    2. O’Lone E,
    3. Kaushik T,
    4. McCafferty K,
    5. Yaqoob MM
    : Acidosis: Progression of chronic kidney disease and quality of life. Pediatr Nephrol 30: 873–879, 2015 https://doi.org/10.1007/s00467-014-2873-9
    OpenUrl
  42. ↵
    1. Kovacic V,
    2. Roguljic L,
    3. Kovacic V
    : Metabolic acidosis of chronically hemodialyzed patients. Am J Nephrol 23: 158–164, 2003 https://doi.org/10.1159/000070205
    OpenUrlCrossRefPubMed
  43. ↵
    1. Mattman A,
    2. Eintracht S,
    3. Mock T,
    4. Schick G,
    5. Seccombe DW,
    6. Hurley RM,
    7. White CT
    : Estimating pediatric glomerular filtration rates in the era of chronic kidney disease staging. J Am Soc Nephrol 17: 487–496, 2006 https://doi.org/10.1681/ASN.2005010034
    OpenUrlAbstract/FREE Full Text
  44. ↵
    1. Mian AN,
    2. Schwartz GJ
    : Measurement and estimation of glomerular filtration rate in children. Adv Chronic Kidney Dis 24: 348–356, 2017 https://doi.org/10.1053/j.ackd.2017.09.011
    OpenUrlCrossRefPubMed
  45. ↵
    1. den Bakker E,
    2. Gemke RJBJ,
    3. Bökenkamp A
    : Endogenous markers for kidney function in children: A review. Crit Rev Clin Lab Sci 55: 163–183, 2018 https://doi.org/10.1080/10408363.2018.1427041
    OpenUrlPubMed
  46. ↵
    1. Schwartz GJ,
    2. Work DF
    : Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol 4: 1832–1843, 2009 https://doi.org/10.2215/CJN.01640309
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Ingulli EG,
    2. Mak RH
    : Growth in children with chronic kidney disease: Role of nutrition, growth hormone, dialysis, and steroids. Curr Opin Pediatr 26: 187–192, 2014 https://doi.org/10.1097/MOP.0000000000000070
    OpenUrlCrossRefPubMed
  48. ↵
    1. Chand DH,
    2. Vitale VS
    : Growth and nutrition in children with chronic kidney disease. Minerva Pediatr 62: 285–294, 2010
    OpenUrlPubMed
  49. ↵
    1. Norman LJ,
    2. Coleman JE,
    3. Macdonald IA,
    4. Tomsett AM,
    5. Watson AR
    : Nutrition and growth in relation to severity of renal disease in children. Pediatr Nephrol 15: 259–265, 2000 https://doi.org/10.1007/s004670000465
    OpenUrlCrossRefPubMed
  50. ↵
    1. Brewer ED
    : Growth of small children managed with chronic peritoneal dialysis and nasogastric tube feedings: 203-month experience in 14 patients. Adv Perit Dial 6: 269–272, 1990
    OpenUrlPubMed
  51. ↵
    1. Bonthuis M,
    2. Groothoff JW,
    3. Ariceta G,
    4. Baiko S,
    5. Battelino N,
    6. Bjerre A,
    7. Cransberg K,
    8. Kolvek G,
    9. Maxwell H,
    10. Miteva P,
    11. Molchanova MS,
    12. Neuhaus TJ,
    13. Pape L,
    14. Reusz G,
    15. Rousset-Rouviere C,
    16. Sandes AR,
    17. Topaloglu R,
    18. Van Dyck M,
    19. Ylinen E,
    20. Zagozdzon I,
    21. Jager KJ,
    22. Harambat J
    : Growth patterns after kidney transplantation in European children over the past 25 years: An ESPN/ERA-EDTA Registry study. Transplantation 104: 137–144, 2020 https://doi.org/10.1097/TP.0000000000002726
    OpenUrlPubMed
  52. ↵
    1. Boehm M,
    2. Riesenhuber A,
    3. Winkelmayer WC,
    4. Arbeiter K,
    5. Mueller T,
    6. Aufricht C
    : Early erythropoietin therapy is associated with improved growth in children with chronic kidney disease. Pediatr Nephrol 22: 1189–1193, 2007 https://doi.org/10.1007/s00467-007-0472-8
    OpenUrlCrossRefPubMed
  53. ↵
    1. Diskin CJ,
    2. Stokes TJ,
    3. Dansby LM,
    4. Radcliff L,
    5. Carter TB
    : Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialysis patients? Nephrology (Carlton) 11: 394–399, 2006 https://doi.org/10.1111/j.1440-1797.2006.00674.x
    OpenUrlCrossRefPubMed
  54. ↵
    1. Mahan JD,
    2. Warady BA; Consensus Committee
    : Assessment and treatment of short stature in pediatric patients with chronic kidney disease: A consensus statement. Pediatr Nephrol 21: 917–930, 2006 https://doi.org/10.1007/s00467-006-0020-y
    OpenUrlCrossRefPubMed
  55. ↵
    1. Brady JP,
    2. Hasbargen JA
    : A review of the effects of correction of acidosis on nutrition in dialysis patients. Semin Dial 13: 252–255, 2000 https://doi.org/10.1046/j.1525-139x.2000.00068.x
    OpenUrlCrossRefPubMed
  56. ↵
    1. Roderick P,
    2. Willis NS,
    3. Blakeley S,
    4. Jones C,
    5. Tomson C
    : Correction of chronic metabolic acidosis for chronic kidney disease patients. Cochrane Database Syst Rev (1): CD001890, 2007 https://doi.org/10.1002/14651858.CD001890.pub3
  57. ↵
    1. Silverstein DM
    : Growth and nutrition in pediatric chronic kidney disease. Front Pediatr 6: 205, 2018 https://doi.org/10.3389/fped.2018.00205
    OpenUrl
    1. Querfeld U,
    2. Anarat A,
    3. Bayazit AK,
    4. Bakkaloglu AS,
    5. Bilginer Y,
    6. Caliskan S,
    7. Civilibal M,
    8. Doyon A,
    9. Duzova A,
    10. Kracht D,
    11. Litwin M,
    12. Melk A,
    13. Mir S,
    14. Sözeri B,
    15. Shroff R,
    16. Zeller R,
    17. Wühl E,
    18. Schaefer F; 4C Study Group
    : The Cardiovascular Comorbidity in Children with Chronic Kidney Disease (4C) study: Objectives, design, and methodology. Clin J Am Soc Nephrol 5: 1642–1648, 2010 https://doi.org/10.2215/CJN.08791209
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Kidney360: 3 (4)
Kidney360
Vol. 3, Issue 4
28 Apr 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article

Thank you for your interest in spreading the word on American Society of Nephrology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Impact of Metabolic Acidosis and Alkali Therapy on Linear Growth in Children with Chronic Kidney Disease: What Is the Current Evidence?
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Impact of Metabolic Acidosis and Alkali Therapy on Linear Growth in Children with Chronic Kidney Disease: What Is the Current Evidence?
Emma H. Ulrich, Rahul Chanchlani
Kidney360 Apr 2022, 3 (4) 590-596; DOI: 10.34067/KID.0000072022

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Impact of Metabolic Acidosis and Alkali Therapy on Linear Growth in Children with Chronic Kidney Disease: What Is the Current Evidence?
Emma H. Ulrich, Rahul Chanchlani
Kidney360 Apr 2022, 3 (4) 590-596; DOI: 10.34067/KID.0000072022
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Strengths
    • Limitations
    • Conclusions
    • Disclosures
    • Funding
    • Acknowledgments
    • Author Contributions
    • Footnotes
    • References
  • Figures & Data Supps
  • Info & Metrics
  • View PDF

More in this TOC Section

  • Is There One Best Way to Define AKI?
  • Outcomes Associated with Hypernatremia at Admission in Hospitalized Persons
  • ASK1 Inhibitor in Chronic Kidney Disease Therapy: From Bench to Bedside
Show more Editorial

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Longitudinal Associations between Low Serum Bicarbonate and Linear Growth in Children with CKD
  • Google Scholar

Keywords

  • chronic kidney disease
  • acidosis
  • alkali
  • children
  • end stage kidney disease
  • growth
  • height

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • Kidney360
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About Kidney360
  • Kidney360 Email Alerts
  • Kidney360 Podcasts
  • Kidney360 RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Subscribe to JASN and CJASN
  • Wolters Kluwer Partnership

© 2022 American Society of Nephrology

Online ISSN - 2641-7650

Powered by HighWire